Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 880-884

  Leitner, Judith M ^a   Meyer, Brigitte ^a   Fuhrmann, Valentin ^a   Saria, Katrin ^a   Zuba, Clara ^a   Jäger, Walter ^b   Böhmdorfer, Michaela ^b   Thalhammer, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute renal failure; Antifungal treatment; Renal replacement therapy

Indexed keywords

ANIDULAFUNGIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; RECOMMENDED DRUG DOSE;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHEMOPREVENTION; ECHINOCANDINS; FEMALE; HEMOFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; RENAL INSUFFICIENCY;

EID: 79952779286     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq545     Document Type: Article

References (21)

1. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5: 120-35.
2. Sabol K, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag 2008; 4: 71-8.
3. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235-43.
4. Ostrosky-Zeichner L. Prophylaxis for invasive candidiasis in the intensive care unit: is it time? Crit Care Med 2005; 33: 2121-2.
5. Dowell JA, Stogniew M, Krause D et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 461-70.
6. Gattringer R, Meyer B, Heinz G et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother 2006; 58: 367-71.
7. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004; 2: 499-508.
8. Dowell JA, Knebel W, Ludden T et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590-8.
9. Joseph JM, Kim R, Reboli AC. Anidulafungin: a drug evaluation of a new echinocandin. Expert Opin Pharmacother 2008; 9: 2339-48. 10.
10. Anidulafungin (Eraxis). Prescribing Information. 2007. Pfizer.
11. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
12. Antachopoulos C, Meletiadis J, Sein T et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008; 52: 321-8.
13. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805-12.
14. Gabutti L, Taminelli-Beltraminelli L, Marone C. Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers. Eur J Clin Pharmacol 1997; 53: 123-6.
15. Meyer B, Ahmed el Gendy S, Delle Karth G et al. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res 2003; 26: 135-40.
16. Meyer B, Traunmuller F, Hamwi A et al. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-hused highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Int J Clin Pharmacol Ther 2004; 42: 556-60.
17. Fuhrmann V, Schenk P, Jaeger W et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 2004; 54: 780-4.
18. Fuhrmann V, Schenk P, Jaeger W et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2007; 60: 1085-90.
19. Muhl E, Martens T, Iven H et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-8.
20. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005; 49: 2421-8.
21. Banyai M, Thalhammer F, El-Menyawi I et al. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. Clin Pharmacol Ther 2000; 67: 368-72.